| Patent Number |
Title Of Patent |
Date Issued |
| 5958413 |
Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination t |
September 28, 1999 |
| A combined preparation for simultaneous combined, simultaneous separate, or sequential use in the therapy of prophylaxis of disorders associated with undesirable high levels of TNF, e.g. septic or endotoxic shock and immunoregulatory and inflammatory disorders, which comprises an antibod |
| 5824874 |
Antifungal polypeptide and process for its production |
October 20, 1998 |
| The polypeptide with the sequence (SEQ ID NO:1)Ala-Thr-Tyr-Asn-Gly-Lys-Cys-Tyr-Lys-Lys-Asp-Asn-Ile-Cys-Lys-Tyr-Lys-Ala-Gln -Ser-Gly-Lys-Thr-Ala-Ile-Cys-Lys-Cys-Tyr-Val-Lys-Lys-Cys-Pro-Arg-Asp-Gly-Al a-Lys-Cys-Glu-Phe-Asp-Ser-Tyr-Lys-Gly-Lys-Cys-Tyr-Cyscan be produced by the fermentation of Asp |
| 5631259 |
Cycloalkltriols containing cyclic substituents, processes and intermediate products for their pr |
May 20, 1997 |
| Cycloalkyltriols containing heterocyclic substituents, in particular cyclopentyl- and cyclohexyltriols containing heterocyclic substituentsCompounds of the formulae I and II ##STR1## in which the substituents A, R.sup.1, R.sup.2 and R.sup.3 and n have the meanings given, have an anti |
| 5589624 |
Antifungal polypeptide and process for its production |
December 31, 1996 |
| The polypeptide with the sequence (SEQ ID NO: 1)can be produced by the fermentation of Aspergillus giganteus and used as an antifungal agent.Expression of this polypeptide gene in plants strongly inhibits the growth of phytopathogenic fungi on the plant. |
| 5421839 |
Antifungal polypeptide and process for its production |
June 6, 1995 |
| Antifungal polypeptide and process for its productionThe polypeptide with the sequence (SEQ ID NO: 1)Ala-Thr-Tyr-Asn-Gly-Lys-Cys-Tyr-Lys-Lys-Asp-Asn-Ile-Cys-Lys-Tyr-Lys-Ala-Gln -Ser-Gly-Lys-Thr-Ala-Ile-Cys- Lys-Cys-Tyr-Val-Lys-Lys-Cys-Pro-Arg-Asp-Gly-Ala-Lys-Cys-Glu-Phe-Asp-Ser-Ty r-Lys-Gl |
| 5118500 |
Pharmaceutical containing TNF inhibitor |
June 2, 1992 |
| Pharmaceuticals which contain a substance releasing tumor necrosis factor (TNF) are better tolerated and can be given in higher doses when they contain a TNF inhibitor, especially a xanthine derivative. |
